by EPHA | Nov 18, 2019 | Position & Policy Papers
Superbugs cost the life of nearly 90 people every day in the EU and the EEA¹. A serious threat to patient safety, AMR crosses national borders and endangers many healthcare interventions, including life-saving surgical procedures and cancer treatments. The development...
by European Public Health Alliance | Oct 24, 2019 | Opinion
By the European Cancer Leagues Access to Medicines Taskforce In 2016 European cancer societies decided to leave their comfort zone and join the access to medicines debate. They established the ECL Access to Medicines Task Force which has since then become an...
by European Public Health Alliance | Jul 30, 2019 | Opinion
Earlier this year, EPHA published an in-depth review of the existing National Action Plans (NAP) and strategies against antimicrobial resistance (AMR) in the EU and EEA Member States, focusing in particular on the extent to which they have adopted the One Health...
by European Public Health Alliance | May 3, 2019 | Opinion
By Jean-Yves Stenuick, Pharmaceuticals Policy & Projects Officer, Health Care Without Harm (HCWH) Europe The European Commission is failing to mitigate the impact of pharmaceutical pollution, a driver of growing antimicrobial resistance recognised by UN...
by European Public Health Alliance | May 3, 2019 | Opinion
By Rose Gallagher MBE, Professional Lead Infection Prevention & Control, Royal College of Nursing and EPHA Scientific Advisor on Antimicrobial Resistance There’s no doubt that awareness of antimicrobial resistance is increasing – within civil society,...
